Core Insights - The 8th China International Import Expo is currently being held in Shanghai, where Dr. Chen Li, CEO of Hualing Pharmaceutical Technology, highlighted the company's innovative approach to diabetes treatment, integrating Chinese systematic and dialectical methods to develop a groundbreaking diabetes drug [1][2] - Diabetes has a long history, and despite advancements in Western medicine, the number of diabetes patients has surged from 100 million to 589 million, with treatment costs reaching $1 trillion annually [2] - Hualing Pharmaceutical's new drug offers hope for type 2 diabetes patients, with a reported 65% rate of drug-free remission after one year of treatment [2] - The reform of China's drug approval system has significantly increased the share of innovative drugs approved in the global market, rising from 5% in 2015 to 38% last year [3] Company Insights - Hualing Pharmaceutical focuses on diabetes research and has developed the world's first diabetes drug that aims to restore blood sugar homeostasis by repairing the body's blood sugar sensors [2] - The company emphasizes the importance of integrating traditional Chinese medical philosophies with modern scientific approaches to address global health challenges [1][2] Industry Insights - The diabetes treatment market is projected to continue growing over the next decade, driven by the increasing prevalence of diabetes and its associated complications [2] - The significant rise in the number of diabetes patients and the associated healthcare costs highlight the urgent need for innovative treatment solutions in the pharmaceutical industry [2][3]